TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05540912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D064+D701
Description: Reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 1
Description: Test 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828 Formulation 2
Description: Test 2
Study: NCT05756816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurePulse VSP
Description: A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VSP placed on the volunteer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurePulse VS
Description: A controlled and stepwise reduction in oxygen blood levels in healthy volunteers, with the SurePulse VS placed on the volunteer.
Study: NCT04822792

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test
Study: NCT03400306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, capsule
Description: capsule; 50 mg or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, capsule
Description: capsule; 50 mg or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, capsule
Description: capsule; 50 mg or 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, tablet
Description: tablet; 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib, tablet
Description: tablet; 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous
Study: NCT05244278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic-GI genius (CADe system for detecting colorectal polyps)
Description: Medtronic-GI genius: AI will provide real-time feedback throughout each colonoscopy procedure and alert endoscopists to the presence of a polyp in the endoscopy field by displaying a bounding box on the same screen.
Study: NCT05314036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized test meal
Description: During this study visit, a standardized test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 2 hours after test meal.
Study: NCT05842226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-teaching enriched with standard patient
Description: The practice group will be shared the 4 most common symptoms in palliative care nursing: pain, fatigue, respiratory distress and loss of appetite. The practice group will be 5 groups and there will be 4 students in each group. During the practice, each student will provide patient education about only one symptom. The standard patient will participate in the intervention in the application laboratory and the students will participate in the intervention in the computer environment. Video recordings will be taken while the students are giving education. After watching the experts, peers and their own video with the micro-teaching group evaluation form, the student himself/herself will make an evaluation. At the same time, a lecturer from outside the research will fill in the Standard Patient Check-List Evaluation Form. The application will be repeated one week later.
Study: NCT06180304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The indoor physical exercise program was carried out in a gym with weight machines. The physical exercise program was divided into four parts. Part I: playful game or shuttle run (5 to 7 minutes). Part II: aerobic training (treadmill; 10 minutes; 40% to 80% of Heart Rate Reserve; between 12 to 17 according to the Borg Rating Of Perceived Exertion Scale; between 5 to 8 according to the Borg Category-Ratio 10 Scale. Part III: strength training (more or less 25 minutes; Leg Press + Chest Press + Leg Extension + Lat Pull Down + Leg Curl + Shoulder Press; 40-80% of 3 maximum repetitions; 10-15 reps; 2-3 sets). Part IV: 4 static stretches (30 to 60 seconds each).
Study: NCT06233045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Test product
Description: Dapagliflozin tablet 10 mg Test product Manufactured by: ZYDUS LIFESCIENCES LIMITED, India
Study: NCT06233045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin-Reference product
Description: Dapagliflozin tablet 10 mg Reference product Manufactured by: ASTRAZENECA PHARMACEUTICALS LP, USA
Study: NCT05608850

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Then Stretch
Description: This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise Then Stretch
Description: This arm (sequence) will perform an anti-gravity kinetic chain intervention and then a passive, partner-assisted stretching intervention, separated by a one-week washout period.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretch Then Exercise
Description: This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretch Then Exercise
Description: This arm (sequence) will perform a passive, partner-assisted stretching intervention and then an anti-gravity kinetic chain intervention , separated by a one-week washout period.
Study: NCT05802368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality group
Description: a 30-minute VR-based training session utilizing Kinect Xbox after the session of traditional physical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: Traditional physical therapy, 30-minutes physical therapy exercise program each week with 48-hour intervals at least
Study: NCT05085626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib+chidamide
Description: Arms A will be treated with fluzoparib in combination with cedaramide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib+camrelizumab
Description: Arms B will be treated with fluzoparib in combination with camrelizumab
Study: NCT05012800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 21, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine
Description: Coronavirus vaccine was inoculated on day 0 and day 21, respectively.
Study: NCT06218225

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum
Description: 1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of study product Cycle 3 - first 15 days washout, remaining 15 days use of study product 4th cycle - 30-day washout

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st cycle - 30 days continuous use Cycle 2 - first 15 days washout, remaining 15 days use of placebo Cycle 3 - first 15 days washout, remaining 15 days use of placebo 4th cycle - 30-day washout
Study: NCT06186141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout
Study: NCT06517667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icross tear substitute
Description: Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
Study: NCT06051097

Intervention type: DIAGNOSTIC_TEST
Intervention: sleep study
Description: over-night polysomnography

Intervention type: DIAGNOSTIC_TEST
Intervention: sleep study
Description: over-night polysomnography
Study: NCT06517667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyabak tear substitute
Description: Patients were instructed to instill 1 drop of 0.15% hyaluronic acid substitute into each eye 3 times per day for 3 months.
Study: NCT05815654

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Warm Palace Analgesic Point Sticker
Description: The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm Palace Analgesic Point Sticker
Description: The Warm Palace Analgesic Point Sticker is developed by Changchun University of Traditional Chinese Medicine
Study: NCT05804045

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pimicotinib(ABSK021)
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib(ABSK021)
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule
Study: NCT05654909

Intervention type: PROCEDURE
Intervention: Prehospital assessment unit
Description: The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
Study: NCT05895253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrotactile ground-contact feedback
Description: Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrotactile ground-contact feedback
Description: Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
Study: NCT04810819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;
Description: Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04523649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote atrial fibrillation screening with handheld single lead ECG recorder
Description: Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
Study: NCT06214845

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood cell EXchange (REX)
Description: A single automated REX will be performed, as soon as possible after randomization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell EXchange (REX)
Description: A single automated REX will be performed, as soon as possible after randomization.
Study: NCT04666259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Study: NCT05094674

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Sample analysis
Description: The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
Study: NCT05766917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer education group
Description: Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
Study: NCT04262596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Consulting System
Description: Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A traditional patient decision aid brochure
Description: Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
Study: NCT06452719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 10 mg orally daily for three consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
Study: NCT05012722

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement
Description: All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement
Description: All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement
Description: All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
Study: NCT05263232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural or artificial office light exposure
Description: Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural or artificial office light exposure
Description: Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
Study: NCT05085613

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
Study: NCT05349110

Intervention type: DEVICE
Intervention: Computer-aided diagnosis (CADx) systems
Description: * AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~* CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan).
Study: NCT06527183

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin punch biopsy to demonstrate small fiber neuropathy
Description: Skin punch biopsy to assess intrapidermal nerve fiber density

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin punch biopsy to demonstrate small fiber neuropathy
Description: Skin punch biopsy to assess intrapidermal nerve fiber density

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin punch biopsy to demonstrate small fiber neuropathy
Description: Skin punch biopsy to assess intrapidermal nerve fiber density
Study: NCT04711525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)
Description: The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
Study: NCT05584891

Intervention type: PROCEDURE
Intervention: mastoidectomy and mastoid oblitration
Description: Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.

Intervention type: PROCEDURE
Intervention: mastoidectomy and mastoid oblitration
Description: Forty pediatric patients with cholesteatoma indicated for radical mastoidectomy or modified radical mastoidectomies will be enrolled in our study and we will be grouped into two groups: one will undergo radical mastoidectomy alone and their operation results will be compared to other group which includes twenty pediatric patients with mastoid obliteration operation.
Study: NCT04716699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection per standard of care
Study: NCT04711525

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Standard health education
Description: The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.